Study of XZ120 for advanced solid tumors and lymphoma
Part of Cancer clinical trials.
This trial tests a new drug called XZ120, alone or with standard chemotherapy, for people with advanced breast cancer, a type of lymphoma (DLBCL), or other solid tumors that have stopped responding to treatment. The goal is to see if the drug shrinks tumors or controls the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have advanced breast cancer, a specific type of lymphoma (DLBCL), or another advanced solid tumor that standard treatments have stopped working for
- Your daily activity level is high enough to do light housework or office work (ECOG 0 or 1)
- Your heart is pumping well (LVEF 50% or higher)
- Your blood counts and liver/kidney function are within certain limits (your doctor will check this)
- You have not taken more than a certain total amount of doxorubicin or similar drugs in the past
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests XZB-0004 in adults with solid cancers to check safety and how the body responds to the drug. It may help doctors learn whether this treatment could be useful for certain tumor types, including non-small cell lung cancer.
This trial tests a new drug, XB628, alone or together with another drug called zanzalintinib, in people whose advanced solid tumor has continued to grow after at least one prior treatment. The goal is to see if these combinations can shrink tumors or slow their growth.
This trial tests a new drug called ZE94-0605 for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if it is safe and can shrink tumors.
This trial tests an experimental drug, QLS1209, for people with advanced solid tumors that have specific genetic changes (CCNE1 amplification, FBXW7 mutation, or PPP2R1A mutation). It aims to see if the drug is safe and effective for those who have not responded to standard treatments or have no standard options.
This Phase 1/2 trial tests XTX301, a study treatment, in people with advanced solid tumors (cancers) that have already been treated and are not controlled by standard options. It may help if your cancer matches one of the study groups and you meet safety and test-tissue requirements.
This trial tests a new drug, JBZ-001, to see how safe it is for people with advanced solid tumors or certain types of lymphoma that have not improved with standard treatments. It's a first-in-human study, so participants will help doctors learn about the drug's side effects and the right dose.
Hear when a new Advanced Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.